UiPath: The Rally Has Erased the Discount — September's Quarter Has to Prove It

UiPath: The Rally Has Erased the Discount — September's Quarter Has to Prove It

Daniel Dines, the founder, CEO, and chairman of UiPath (NYSE: PATH), sold roughly 1.4 million shares for about $22.5 million on August 19, and the initial read on that Form 4 is a gut check for a stock that has climbed a long way off its spring low. I would not give the trade itself much weight. The sale ran through a Rule 10b5-1 plan — a trading arrangement set up well in advance so an insider can diversify without acting on nonpublic information — and after selling, he still directly owns about 26.5 million shares, a position worth more than $400 million and equal to roughly 5% of the company. A founder trimming a twentieth of his stake at market is standard diversification, not a verdict on the company. The telling part of this filing is the other side of the ledger: Dines collected about $16.07 per share, which is also the problem the stock now has.

The shares repriced themselves in a quarter

UiPath bottomed at $9.20 in mid-May, and now trades near $16, roughly 56% higher over just the last twenty trading days and up about 49% over the last 120, with a 5-day dip of roughly 4% as the momentum cools. The August leg arrived on a sector-wide software bounce, when UiPath jumped 7.4% to $16.39 on volume near 86.7 million shares in the same session that lifted JFrog, Rubrik, and SentinelOne. Momentum stocks rising together is not a company-specific catalyst, and it has carried the shares cleanly above their 50- and 200-day moving averages. Whatever this business deserves, it no longer trades where the market used to price it — and it is still slightly in the red for the year, which shows how far the rebound had to travel.

The numbers the rally is paying for

The bull case is real, not fabricated. In the fiscal first quarter ended April 30 — reported May 28 — UiPath grew revenue 17% year over year to $418 million, roughly $21 million ahead of the Street, and posted its first-ever GAAP operating profit of about $28 million, with non-GAAP operating income of $92 million, a 22% margin. Annualized recurring revenue (ARR) — the run-rate value of active contracts and the headline top-line for a subscription business — reached $1.901 billion, up 12%, and remaining performance obligations (contracted but not-yet-recognized revenue) rose 15%. Dollar-based net revenue retention of 109% shows existing customers are still spending more than they did a year ago, and management reports that 16 of its top 20 deals in the quarter included AI components. On its face, that is the strongest quarter this company has printed in years, and the reason investors have stopped treating "agentic AI" as a threat to UiPath's robotic process automation franchise and started treating it as the tailwind.

But the guidance puts a ceiling on the reacceleration

Here is where the story gets narrower than the stock move. Net new ARR — the dollars added to the recurring base each quarter, the closest thing UiPath has to an order book — was just $49 million in Q1. That is roughly the same per-quarter pace the company averaged in fiscal 2026, when it added $186 million of net new ARR for the year, and it is below the $70 million added in the fiscal fourth quarter. And the company's own outlook says the deceleration is coming: management guided the fiscal second quarter — the July quarter it reports on September 3 after the market close — to revenue of $395 million to $400 million. Against the $361.7 million UiPath recorded in the same quarter a year ago, that is about 9% to 11% growth, a steep step down from Q1's 17%. The full-year revenue guide of roughly $1.78 billion implies full-year growth near 10%, down from the 13% UiPath delivered in fiscal 2026, when revenue hit $1.61 billion. Even the year-end ARR target of about $2.06 billion is only 11% above where the company ended January, in line with, not better than, its recent pace. Management is, in effect, telling buyers that Q1's acceleration was a beat-and-raise quarter, not proof of a new regime.

A multiple that is no longer discounted

At $16, UiPath carries a market capitalization near $8.3 billion and an enterprise value near $7.0 billion — enterprise value being the market value of the equity plus net debt, which in this case mostly backs out the cash pile — working out to roughly 4 times trailing sales, about 30 times trailing EBITDA, and around 25 times trailing earnings. That is not an outrageous price for a software company with an 83% gross margin, no debt, and free cash flow of about $375 million over the trailing twelve months, a roughly 22% free-cash-flow margin. But expensive-and-justified is different from cheap, and cheap is what this stock used to be. The average sell-side target sits at $13.87, below the market price, with the consensus rating stuck at Hold; DA Davidson carries a $12 target and BofA a $13 target even as RBC nudged its number up to $15 in mid-August. When a stock runs above the average analyst price target, the marginal buyer is no longer getting paid to tolerate the risks — he is funding an expected acceleration that the analyst community has not yet validated in its own models.

The cushions that keep this a Hold, not a Sell

None of this justifies selling the stock short or unloading it with prejudice. UiPath's balance sheet is a genuine floor: about $1.42 billion in cash and marketable securities against no debt, and management has been an aggressive buyer of its own shares, repurchasing well over $200 million in the April quarter alone. It finished one $1 billion buyback program and authorized a new $500 million program, which tells you the board believes its stock is cheap relative to cash generation. First-time GAAP profitability, a 90% software gross margin, a net revenue retention rate that ticked up from 107% to 109% between the fiscal fourth quarter and the first quarter — the fundamental trajectory is improving. The complaint here is purely one of price versus proof, and that is a timing problem, not a thesis problem.

What September 3 has to prove

The September 3 report is the catalyst that decides whether this rally is a repricing or a head-fake, and it is two weeks away. The number to watch is net new ARR: it needs to consistently clear the $50 million-to-$60 million zone to establish that the agentic automation cycle is converting pilots into paid contracts at scale. Management has already flagged that the quarter is "softer sequentially" — guidance beneath Q1's actual revenue — so investors should expect the sequel to the beat-and-raise to be more muted. If net new ARR inflects higher anyway, the reacceleration is durable and today's multiple starts to look supportable. If Q2 merely delivers a garden-variety close to guidance, a stock that has risen more than 70% off its May low has given up its margin of safety and has room to give back its technical spike.

My call is to hold and wait rather than chase $16. The asymmetry that made UiPath interesting was available in May and early July, when the market priced the business for stagnation at $10 to $12 and the downside was cushioned by the same balance sheet and buyback math that exist today. At $16, with the stock above the average analyst target and the acceleration resting on one quarter of evidence, the risk/reward has flipped to roughly even, and the next identifiable crack in net new ARR will punish a chart that has strayed this far from its moving averages. The founder's Form 4 is not the signal — the signal is the price he could get for those shares, and the same logic that made a scheduled trim convenient at $16 is the logic that says the easy money in this stock has already been made.

Either a pullback into the low teens, or a September 3 quarter that pushes net new ARR decisively past the fiscal-year pace, would rebuild the setup worth buying. Until one of those happens, the disciplined position is on the sidelines.